Edwin Elmhirst
Data Journalist

Latest From Edwin Elmhirst
Investment In New Products: Looking Beyond The R&D Line
Johnson & Johnson and Roche lead the most recent Scrip 100 ranking for R&D spend, but a look beyond investment in internal development highlights a big year for Pfizer and Bristol Myer Squibb.
Lilly’s Zepbound: The Biggest-Selling Drug In The World, Ever?
Humira currently holds the record as the bestselling drug ever. But Keytruda is coming for its crown – and beyond that, Zepbound.
Tempest Changes The Atmosphere
An analysis of shareholders’ reactions to clinical data shows a generally dismal environment punctuated by a few huge positive moves.
It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever
But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.
As Time Ticks, Industry Edges Closer To The Big Patent Cliff
Big pharma manufacturers are approaching a period that will be marked by the loss of exclusivity of many big-selling brands. All of the players are looking for ways to navigate the loss of revenues.
A Closer Look: Commercial Impact For Drugs Up For Medicare Price Negotiation
An infographic looking at commercial factors for the 10 drugs chosen for Medicare price negotiation in 2026 under the Inflation Reduction Act (IRA). The graphics below review the valuations of these drugs, both past and forecast, as well as their relative contributions to the top-lines of the companies that own them.